Show
Sort by
-
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)
-
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy
-
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
-
- Journal Article
- A1
- open access
Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients
-
Identification of novel, rare markers for poor survival in high-risk neuroblastoma patients by merging and reanalysing existing datasets
-
Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients
-
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
-
- Journal Article
- A1
- open access
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
-
Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients
-
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma